Bharat Parenterals Ltd Q4 FY2026 Concall Summary

Key Takeaways

• FY26 was a deliberate bridge year: Consolidated revenue was flat at INR 345.4 cr, but the mix transformed as Innoxel grew 174% and Varenyam turned profitable, while the standalone business absorbed one-time disruptions to prepare for FY27 regulatory inspections.
• Innoxel cleared for takeoff: The facility received US FDA and EUGMP clearance with zero critical observations, turned EBITDA-positive in Q4, and guided for 35–45% revenue growth in FY27 driven by licensing milestones and first commercial CMO supplies.
• Standalone business took the pain upfront: Revenue fell ~23% as export tenders slipped, low-margin business was shed, and production lines were shut for upgradation. Management expects only partial recovery in FY27, with full recovery crossing FY25 levels in FY28.
• The group is betting on operating leverage: Innoxel and Varenyam both turned profitable this year while still investing for growth. Varenyam's PCPM rose 31% and corporate coverage deepened, setting up what management calls the operating leverage phase.
• What to watch next quarter: Whether the first CMO product commercializes on schedule in Q2 FY27, the pace of standalone tender conversion from the INR 171 cr order book, and any further timeline slippage at Varenyam Biolifesciences.

The Bridge Year: Why FY26 Looked Flat But Wasn't

• Consolidated revenue held steady at INR 345.4 cr vs INR 340 cr, but the composition shifted decisively toward the new businesses while the legacy standalone business shrank.
• Standalone revenue fell ~23% to INR 234 cr from INR 304 cr, driven by three deliberate or one-time factors: export tenders deferred into next year, a conscious exit from low-margin volume businesses, and production lines taken down for upgradation work across all three blocks, costing nearly two months of production days.
• Standalone profitability held up despite the top-line drop: EBITDA of INR 21 cr at 9% margin and PAT of INR 16 cr at 6.8% margin, helped by a 28% reduction in finance cost and 40% lower other expenses YoY.
• The \$27 million tender order that was expected in July arrived only in the first week of March 2026, causing the main delay in standalone performance. Supply has now started.
• Capacity headroom removes capex pressure: Standalone utilization stands at 48%/21%/24% across lines, so the 10–15% guided growth for FY27 requires no fresh capex.

Desai: "We expected the order in July of last year, but unfortunately, we got the orders somewhere in March first week of 2026, which got us the, which is where the main delay happened."

Innoxel: The Inflection Has Arrived

• Revenue grew 174% to INR 72.4 cr from INR 26.4 cr, largely from licensing and milestone payments. The cumulative deal count reached 42, with 23 signed in FY26 alone (7 out-licensing, 16 CMO-CDO).
• Regulatory clearance unlocks commercial supply: The facility received its US FDA establishment inspection report and was cleared by FAMHP, the Belgian EUGMP regulator, with zero critical and zero major observations. It is now cleared for commercial supply to both the US and selected European markets.
• EBITDA turned the corner: The full-year EBITDA loss narrowed to INR 6.9 cr from INR 30.4 cr. In Q4 FY26, Innoxel turned EBITDA-positive for the first time at INR 1.4 cr.
• First CMO commercialization is imminent: Two products are expected to commercialize this year, the first in Q2 FY27 and the second between Q3 and Q4 FY27. For one project, all six milestones are complete and approval has been received.
• Two 505(b)(2) assets are progressing toward filing: Exhibit batches are complete and on stability. One asset has finished its European bioequivalence study and files in Europe this month, with a US filing targeted for Q3 FY27. The second, an oral liquid, targets a Q4 FY27 filing. Both will be filed in the partner's name.
• FY28 is the manufacturing revenue inflection: The first year of manufacturing revenues for Innoxel's own products arrives in FY28, but management declined to quantify it, citing the need for more clarity on regulatory and approval timelines from the FDA and partners.

Desai: "It's just one quarter, so I don't want to overclaim it, but for those of you who have followed Innoxel for some years, this is a meaningful turn."

Standalone Business: A Reset Year With a Two-Year Recovery

• FY27 will be another disrupted year: Two major audit events, PIC/S and EUGMP inspections, are scheduled at the standalone facilities during FY27. The preparatory phase and the inspections themselves will cause production disruption before certifications arrive.
• Recovery is back-end loaded: Management expects only partial recovery in FY27, with full recovery crossing FY25 levels in FY28. The business is guided to grow 10–15% in FY27 with EBITDA margins in the same 10–15% range.
• The order book provides visibility: An order book of INR 171 cr underpins the FY27 guidance, with growth concentrated in Southeast Asia, Africa, and the MENA region.
• Structural mix shift is underway: The standalone business historically grew at a 10–15% CAGR, but structural changes in product mix and business mix over the next 3–4 years are compressing current performance. Peak revenue is expected to reach INR 400–500 cr, but on a 3-to-4-year timeline from a 2030 standpoint.
• A representative office in Vietnam has been opened, expected to support growth in Southeast Asia.

Varenyam: The Domestic Formulation Engine Starts to Fire

• Varenyam Healthcare swung to full-year profitability in a single year: EBITDA of INR 2.5 cr vs a loss of INR 3 cr, and PAT of INR 2.3 cr vs a loss of INR 2.1 cr. This was achieved while investing in expansion, with the field force growing from 190 to 211 and 50 new corporate hospital tie-ups added.
• Operating leverage signals are building: PCPM grew 31% YoY to over INR 3.85 lakhs, and corporate hospital coverage now spans over 7,500 institutions across 26 states.
• FY27 is an investment year, not a margin year: A new division is being launched in gynecology, requiring fresh hiring, training, and new product launches. Seven new product launches are planned, including Remishot, billed as India's first made-in-India product in its category. The field force is expected to expand beyond 250 people.
• Varenyam Biolifesciences timeline has slipped: The facility under construction, with an approved budget of ~INR 160 cr and ~INR 33 cr of CWIP incurred (~20% of cost), is running at least one quarter behind schedule due to geopolitical disturbance. Civil works are at 50% and equipment procurement at ~40%. Commissioning is now targeted for September 2027, with line validation by March 2028, first EUGMP filing in Q1 FY29, and first commercial supply in Q4 FY29.

Desai: "When PCPM is rising and corporate coverage is deepening, that's when you get the operating leverage to come through. We expect FY '27 to start showing that."

Margin Architecture: Where the Profitability Will Come From

• Consolidated EBITDA expanded 485% to INR 15.8 cr from INR 2.7 cr, overwhelmingly driven by Innoxel narrowing its EBITDA loss by INR 23.5 cr.
• Innoxel margin expansion in FY27 will be driven primarily by milestone payments, not commercial supply. Commercial revenues will come from only two or three products during the year and are not expected to be as meaningful as licensing and milestone income. With a larger top line and a fixed cost base, margin expansion is structural.
• Varenyam Healthcare is guided to 8–13% EBITDA margins in FY27, reflecting the cost of rapid expansion. The new division launch and field force build-out will weigh on margins before operating leverage kicks in.
• Standalone margins are guided to 10–15% alongside 10–15% revenue growth, implying no dramatic recovery in profitability during the inspection-disrupted year.
• Sugammadex contributed over INR 10 cr in revenue in FY26. The product, India's first 100 mg per ml version and the only one with a three-year shelf life, is a differentiated asset in the domestic portfolio.

Guidance & Commitments

Key Metrics